Clinical and Serological Characteristics of Vaccine-Associated Immune Thrombocytopenia Following COVID-19 Vaccination
Notice bibliographique
Résumé
Introduction: Vaccine-associated immune thrombocytopenia (VA-ITP) is a serious hematological complication that re-emerged during COVID-19 vaccination campaigns and continues to complicate vaccine safety. The mechanisms of VA-ITP are unknown, and the associated laboratory and patient outcomes have not been well characterized. In this study, we determined the association of VA-ITP with anti-platelet autoantibodies. Methods: We conducted a retrospective cohort study of adult patients with VA-ITP following COVID-19 vaccination identified from the McMaster ITP Registry between December 2020 and January 2024. VA-ITP was defined as new-onset thrombocytopenia (platelet count <100 x109/L) within 3 months of exposure to vaccination. We excluded patients with vaccine-induced immune thrombotic thrombocytopenia (VITT) and positive anti-PF4 antibodies. Platelet counts, vaccine type, and treatments were collected. Platelet antibody testing was performed using a direct monoclonal antibody immobilization of platelet antigens (MAIPA) assay to detect antibodies against platelet glycoprotein (GP) IIbIIIa and GPIbIX. Anti-PF4 antibodies were also measured in the enzyme-immunoassay (EIA) and in the PF4-enhanced serotonin release assay (PF4-SRA). The data were summarized using descriptive statistics. Results: We identified 6 VA-ITP patients after COVID-19 vaccination from the McMaster ITP Registry. Mean age was 52 years (range 28-70), 2 (33.3%) were female. Culprit vaccines were the ChAdOx1 nCoV-19 adenoviral vector (n=3, 50%; first vaccine only), and the BNT16B2b2 mRNA vaccine [n= 3, 50%; after first (n=1), third (n=1) or fourth vaccine (n=1)]. Median platelet count pre-vaccination was 248 x109/L (IQR 197 - 249 x109/L), and median presenting platelet count was 12 x109/L (IQR 9 - 82 x109/L) at 19.5 days (median; IQR 14 - 23 days) post vaccination. Median lowest platelet count was 7 x109/L (IQR 3 - 11 x109/L), occurring 65 days (median; IQR 57 - 384 days) post vaccination. No patients had thrombosis. Three (50%) of 6 patients had detectable platelet antibodies up to 156 days post-vaccination (range 70 - 247 days). Two patients had anti-GPIbIX only and 1 patient had both anti-GPIbIX and anti-GPIIbIIIa. Two patients had received the adenoviral vector vaccine, and one patient received the mRNA vaccine. Treatments for VA-ITP included corticosteroids (n=6), IVIg (n=5), thrombopoietin receptor agonists (n=3), rituximab (n=2), and splenectomy (n=1). Median number of treatments was 3 (IQR 3 - 4). One patient (16.7%) achieved a durable platelet count response, and 5 patients (83.3%) achieved an initial platelet count response and subsequently relapsed, requiring ongoing treatment at the end of follow up (median, 29.5 months; IQR 21.5 - 31). Among the 3 patients with anti-GPIbIX or anti-GPIIbIIIa antibodies, median number of treatments was 4 (range 3 - 5), median lowest platelet count was 6 x109/L (range 3 - 8 x109/L), and all had relapsed requiring ongoing treatment at the end of follow up. Among the 3 antibody-negative patients, the median number of treatments was 3 (range 2 - 3), median lowest platelet count was 11 x109/L (range 1 - 71 x109/L), and 2 (66.7%) required ongoing treatment at the end of follow up. All 6 patients received a median of 2.5 booster vaccines (IQR 1 - 4) during follow up; 2 patients (33.3%) experienced a decrease in platelet counts ≥20%, but none developed severe ITP. Conclusion: We found that 3 (50%) of 6 patients with VA-ITP after adenoviral vector and mRNA COVID-19 vaccines had detectable anti-platelet antibodies, including 2 patients with anti-GPIbIX and one patient with both anti-GPIbIX and anti-GPIIbIIIa. Antibody-positive VA-ITP tended to be more severe and require more treatment.
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
Comment cette classification a été obtenuedéplier
Prédiction machine sur la base complète
Imitation des enseignantsNi prévalence calibrée, ni vérité terrain. Validation humaine à venir. Le volet Gemma est une étiquette directe du modèle pour chaque travail de la base, lue sur la notice réduite au titre. Le volet Codex est un classifieur appris des 10 348 étiquettes directes de Codex et calibré sur les taux pondérés de l'échantillon; les champs sans appui suffisant ne portent aucun appel Codex. Le mode candidate est l'union des deux volets; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont pas des étiquettes humaines.
Scores du classifieur distillé par catégorie (deux têtes)
| Catégorie | Codex | Gemma |
|---|---|---|
| Métarecherche | 0,000 | 0,002 |
| Méta-épidémiologie (sens strict) | 0,000 | 0,000 |
| Méta-épidémiologie (sens large) | 0,000 | 0,000 |
| Bibliométrie | 0,001 | 0,001 |
| Études des sciences et des technologies | 0,000 | 0,000 |
| Communication savante | 0,000 | 0,000 |
| Science ouverte | 0,000 | 0,000 |
| Intégrité de la recherche | 0,000 | 0,000 |
| Charge utile insuffisante (le modèle a refusé de juger) | 0,002 | 0,000 |
Scores machine (provisoires)
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découleClassification
machine, non validéePrédiction automatique; un appel candidat d’une seule source (Gemma direct ou Codex distillé), pas un consensus.
Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».